lifestyle.clientim.com

Author: Hangzhou Deshi Biotechnology Co., Ltd

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

April 30, 2026
Diagens Biotechnology Raises US$101 Million in Hong Kong IPO; Shares More Than Double on First Day of Trading

March 31, 2026